Table 1.
Baseline and the follow-up characteristics of the study participants
| Overall | hsCRP ≤ 3 mg/L | hsCRP > 3 mg/L | P value | |
|---|---|---|---|---|
| Participant (%) | 86,234 (100) | 70,002 (81.17) | 16,232 (18.83) | |
| Age (year) | 50.57 ± 11.88 | 49.76 ± 11.72 | 54.13 ± 11.93 | < 0.0001 |
| Male [n (%)] | 67,665 (78.47) | 55,317 (79.02) | 12,348 (76.07) | < 0.0001 |
| BMI (kg/m2) | 25.07 ± 3.46 | 24.93 ± 3.38 | 25.66 ± 3.71 | < 0.0001 |
| TC (mmol/L) | 4.95 ± 1.14 | 4.95 ± 1.14 | 4.97 ± 1.11 | 0.045 |
| UA (umol/L) | 287.08 ± 82.65 | 287.04 ± 80.74 | 287.28 ± 90.42 | 0.735 |
| eGFR (ml/min/1.73m2) | 72.32 ± 25.25 | 71.85 ± 24.58 | 74.34 ± 27.85 | < 0.0001 |
| hsCRP (mg/L) | 0.80 (0.30 ~ 2.11) | 0.58 (0.23 ~ 1.19) | 6.30 (4.12 ~ 9.20) | < 0.0001 |
| FBG (mmol/L) | 5.45 ± 1.62 | 5.42 ± 1.52 | 5.57 ± 1.94 | < 0.0001 |
| SBP (mmHg) | 130.23 ± 20.62 | 129.56 ± 20.31 | 133.10 ± 21.68 | < 0.0001 |
| DBP (mmHg) | 83.38 ± 11.67 | 83.19 ± 11.58 | 84.21 ± 11.98 | < 0.0001 |
| Smoking [n (%)] | 33,835 (39.24) | 28,490 (40.70) | 5345 (32.93) | < 0.0001 |
| Drinking [n (%)] | 34,921 (40.50) | 29,577 (42.25) | 5344 (32.92) | < 0.0001 |
| Physical activity [n (%)] | 76,734 (88.98) | 63,306 (90.43) | 13,428 (82.73) | < 0.0001 |
| Proportions of relevant diseases or taking relevant medications at baseline | ||||
| Myocardial Infarction [n (%)] | 965 (1.12) | 732 (1.05) | 233 (1.44) | < 0.0001 |
| Hypertension [n (%)] | 36,992 (42.90) | 28,869 (41.24) | 8123 (50.04) | < 0.0001 |
| Diabetes [n (%)] | 7659 (8.88) | 5708 (8.15) | 1951 (12.02) | < 0.0001 |
| Antihypertensive drugs [n (%)] | 8891 (10.31) | 6820 (9.74) | 2071 (12.76) | < 0.0001 |
| Hypoglycemic drugs [n (%)] | 1915 (2.22) | 1467 (2.10) | 448 (2.76) | < 0.0001 |
| Lipid-lowering drugs [n (%)] | 757 (0.88) | 559 (0.80) | 198 (1.22) | < 0.0001 |
| Proportions of relevant diseases or taking relevant medications during follow-up | ||||
| Myocardial infarction [n (%)] | 1426 (1.65) | 1016 (1.45) | 410 (2.52) | < 0.0001 |
| Hypertension [n (%)] | 28,728 (33.31) | 23,608 (33.72) | 5120 (31.54) | < 0.0001 |
| Diabetes [n (%)] | 11,943 (13.85) | 9336 (13.34) | 2607 (16.06) | < 0.0001 |
| Antihypertensive drugs [n (%)] | 12,843 (14.89) | 9640 (13.77) | 3203 (19.73) | < 0.0001 |
| Hypoglycemic drugs [n (%)] | 4778 (5.54) | 3285 (4.69) | 1493 (9.19) | < 0.0001 |
| Lipid-lowering drugs [n (%)] | 2087 (2.42) | 1530 (2.18) | 557 (3.43) | < 0.0001 |
The measurement data of normal distribution were expressed as mean ± SD. The measurement data of skewed distribution were expressed as median (p25 ~ p75), and the counting data were expressed as number of cases (%). BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; hsCRP, high sensitivity C reactive protein; SBP, systolic blood pressure; TC, cholesterol; UA, uric acid